Bausch Health Companies Inc. Stock
$7.95
0.25%
yesterday
NYSE,
Nov 25, 10:10 pm CET
Bausch Health Companies Inc. Stock price
$7.95
-0.09
1.12%
1M
+1.59
25.00%
6M
-0.07
0.87%
YTD
+1.06
15.38%
1Y
-18.16
69.55%
3Y
-19.75
71.30%
5Y
-136.81
94.51%
10Y
NYSE,
Closing price Mon, Nov 25 2024
-0.02
0.25%
Powered by
ISIN
CA0717341071
Symbol
BHC
Index
Sector
Industry
Key metrics
| Market capitalization | $2.92b |
| Enterprise Value | $24.61b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 23.71 |
| EV/Sales (TTM) EV/Sales | 2.60 |
| P/S ratio (TTM) P/S ratio | 0.31 |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue growth (TTM) Revenue growth | 10.91% |
| Revenue (TTM) Revenue | $9.47b |
Show more
Is Bausch Health Companies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Bausch Health Companies Inc. Stock Analysis
Unlock Scores for Free
Analyst Opinions
8 Analysts have issued a Bausch Health Companies Inc. forecast:
Analyst Opinions
8 Analysts have issued a Bausch Health Companies Inc. forecast:
Buy
13%
Hold
63%
Sell
25%
Financial data from Bausch Health Companies Inc.
| Sep '24 |
+/-
%
|
||
| Revenue | 9,474 9,474 |
11%
11%
|
|
| Gross Profit | 5,614 5,614 |
14%
14%
|
|
| EBITDA | 3,056 3,056 |
8%
8%
|
EBIT (Operating Income) EBIT | 1,767 1,767 |
16%
16%
|
| Net Profit | -178 -178 |
82%
82%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Bausch Health Companies Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bausch Health Companies Inc. Stock News
Positive
Reuters
●
8 days ago
The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan.
Neutral
Accesswire
●
8 days ago
Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the first look at its late-stage RED-C clinical trial program which will be presented at the American Assoc...
Neutral
Business Wire
●
12 days ago
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 94,119,275 units*, or 569,743 pounds, of used contact lenses, eye care and lens care materials in the United S...
Company Profile
Manufactures and markets pharmaceutical products
| Head office | Canada |
| CEO | Thomas Appio |
| Employees | 20,270 |
| Founded | 1994 |
| Website | www.bauschhealth.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
